In the wake of the increase in Current Liabilities in the first quarter 2024, Quick Ratio fell to 0.08 a new company low.

Within Medical Laboratories industry 40 other companies have achieved higher Quick Ratio than Renalytix Plc in first quarter 2024. While Quick Ratio total ranking in the first quarter 2024 has deteriorated compared to the prior quarter from 2631 to 3945.

Explain Quick Ratio?
How much Cash & cash equivalents RNLX�s has?
What are RNLX�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

RNLX Quick Ratio	(Sep 30 2024) Q1	(Jun 30 2024) Q4	(Mar 31 2024) Q3	(Dec 31 2023) Q2	(Sep 30 2023) Q1
Y / Y Current Liabilities Change	-20.83 %	-28.76 %	23.96 %	0.01 %	27.39 %
Y / Y Cash & cash equivalent Change	-93.46 %	-81.05 %	-85.75 %	-76.39 %	-55.19 %
Quick Ratio MRQ	0.08	0.41	0.31	0.4	0.92
RNLX's Total Ranking	# 3945	# 2631	# 2243	# 2638	# 2035
Seq. Current Liabilities Change	4.51 %	-23.31 %	7.66 %	-8.24 %	-5.97 %
Seq. Cash & cash equivalent Change	-80.58 %	-0.51 %	-16.28 %	-59.55 %	-43.76 %

Quick Ratio first quarter 2024 Company Ranking
Within:	No.
Medical Laboratories Industry	# 41
Healthcare Sector	# 919
Overall Market	# 3945

Quick Ratio Statistics
High	Average	Low
9.52	3.98	0.08
(Jun 30 2021)		(Sep 30 2024)

Financial Statements
Renalytix Plc's Current Liabilities	$ 12 Millions	Visit RNLX's Balance sheet
Renalytix Plc's Cash & cash equivalent	$ 1 Millions	Visit RNLX's Balance sheet
Source of RNLX's Sales		Visit RNLX's Sales by Geography

Cumulative Renalytix Plc's Quick Ratio

RNLX's Quick Ratio for the trailling 12 Months

RNLX Quick Ratio	(Sep 30 2024) 12 Months	(Jun 30 2024) 12 Months	(Mar 31 2024) 12 Months	(Dec 31 2023) 12 Months	(Sep 30 2023) 12 Months
Y / Y Current Liabilities TTM Growth	-8.55 %	2.81 %	21.17 %	6.72 %	23.32 %
Y / Y Cash & cash equivalent TTM Growth	-83.32 %	-74.32 %	-62.11 %	-39.91 %	-34.03 %
Quick Ratio TTM	0.3	0.52	0.81	1.35	1.66
Total Ranking TTM	# 3464	# 1954	# 3405	# 3333	# 2749
Seq. Current Liabilities TTM Growth	-5.69 %	-7.71 %	5.05 %	0 %	6.03 %
Seq. Cash & cash equivalent TTM Growth	-44.93 %	-40.93 %	-36.65 %	-19.06 %	-15.21 %

Quick ratio ranking by company, industry and sector >> Back to RNLX Financial Strength Comparisons >> Go to Compare RNLX Quick Ratio to its Competitors

News about Renalytix Plc Quick Ratio

Renalytix Raises $4 Million in Financing to Propel Global Disease Care Innovation

In a major development, Renalytix plc, a leading medical technology firm redefining critical global diseases care, has announced a registered direct offering of ordinary shares. The offering, priced at $0.75 per NASDAQ ADS ($0.375 per common stock share), seeks to raise a total financing amount of up to $4 million. The company has secured DB Capital Partners Healthcare, L.P., a specialized healthcare institutional investor, as the purchaser for this offering.
The initial tranche of the offering consists of 2,666,667 ordinary shares, valued at $1.0 million. The purchaser also has the option to exercise an additional tranche, which would further bolster the aggregate financing size. Both tranches are priced at $0.75 per NASDAQ ADS ($0.375 per ordinary share).

On the trailing twelve months basis In spite of the year on year decrease in RNLX's Current Liabilities to $12.01 millions, cumulative Quick Ratio to 0.3 below the RNLX average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Medical Laboratories industry 36 other companies have achieved higher Quick Ratio than Renalytix Plc. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2024 from 1954 to 3464.

Explain Quick Ratio?
How much Cash & cash equivalents RNLX�s has?
What are RNLX�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Medical Laboratories Industry	# 37
Healthcare Sector	# 932
Within the Market	# 3464

trailing twelve months Quick Ratio Statistics
High	Average	Low
9.22	3.41	0.3
(Jun 30 2021)		(Sep 30 2024)

Companies with similar Quick Ratio in the quarter ending Sep 30 2024, within Medical Laboratories Industry	Quick Ratio	Sep 30 2024 MRQ Cash & cash equivalent	Sep 30 2024 MRQ Current Liabilities
Natera Inc	0.12	$ 29.490 Millions	$ 250.257 Millions
Onemednet Corporation	0.10	$ 1.934 Millions	$ 18.628 Millions
Nrc Health	0.08	$ 3.461 Millions	$ 44.277 Millions
Renalytix Plc	0.08	$ 0.909 Millions	$ 12.013 Millions
LUDWIG ENTERPRISES, INC.	0.02	$ 0.043 Millions	$ 2.466 Millions

Date modified: 2026-08-31T16:10:08+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.